PREDNISOLONE SODIUM METAZOATE

First approved in 1955

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H31O9S.Na
Molecular Weight	566.595
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PREDNISOLONE SODIUM METAZOATE

Structure Search

SMILES

[Na+].C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)C5=CC=CC(=C5)S([O-])(=O)=O

InChI

InChIKey=RWFZSORKWFPGNE-VDYYWZOJSA-M

InChI=1S/C28H32O9S.Na/c1-26-10-8-18(29)13-17(26)6-7-20-21-9-11-28(33,27(21,2)14-22(30)24(20)26)23(31)15-37-25(32)16-4-3-5-19(12-16)38(34,35)36;/h3-5,8,10,12-13,20-22,24,30,33H,6-7,9,11,14-15H2,1-2H3,(H,34,35,36);/q;+1/p-1/t20-,21-,22-,24+,26-,27-,28-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C28H31O9S
Molecular Weight	543.605
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	7 / 7
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA1012&lpg=PA1012&dq=prednazate+prednisolone&source=bl&ots=6IVjr7YAxt&sig=n3FMmropI-ytuQms6m0VusBrXNc&hl=ru&sa=X&ved=0ahUKEwilpZPbib7PAhXMESwKHZaaB18Q6AEIOzAE#v=onepage&q=prednazate%20prednisolone&f=false Retrieved from Dictionary of drugs: Chemical data, structures and bibliographies, edited by J. Elks and C. R. Ganellin, p.1012http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdfhttps://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html | https://humanpara.org/prednisone-and-prednisolone/ | https://www.drugbank.ca/drugs/DB00860http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdfhttps://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/3580023

Prednisolone hemisuccinate is a prodrug of a glucocorticoid agonist prednisolone, which is marketed under trade name Prednisolut in Germany and Austria. Prednisolone hemisuccinate is used in emergency medicine to treate shock due to allergic reaction, insect and snake bites, in neurology to treat brain edema and meningitis, in transplantation medicine to reduce risk of organ refection after kidney transplane, in pneumology to treat acute asthma attack, pulmonary edema, in severe or life-threatening situation in rheumatic diseases.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25965047 \| https://www.drugbank.ca/drugs/DB00860	Agonist 2752	5.7 nM [EC50]
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://dictionary.sensagent.com/prednisone/en-en/	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D08413	Agonist 2752
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Agonist 2752	2.4 nM [Ki]
Glucocorticoid and meneralocorticoid receptor agonists/antagonists 23 Target ID: map07225 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D02156	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Allergic states 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Mycosis fungoides 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Primary or secondary adrenocortical insufficiency 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Hematologic disorders 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Acute leukemia 32 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Multiple sclerosis 107 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Uveitis 28 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Symptomatic sarcoidosis 22 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Rheumatic diseases 31 Sources: https://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html	Primary	Approved 8583	Prednisolone Approved Use Prednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date 1955
Inflammation and pain 22 Sources: (2013) Arthritis: New Insights for the Healthcare Professional, page 345, retrieved from: https://books.google.ru/books?id=YvMIwDn3a20C	Palliative	Approved 8583	Sixtysix-20 Approved Use Antiinflammatory agent
Atopic dermatitis 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Severe erythema multiforme (Stevens-Johnson syndrome) 22 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Congenital adrenal hyperplasia 62 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Crohn's disease 64 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Diamond-Blackfan anemia 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Aggressive lymphoma 24 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202020s003lbl.pdf	Palliative	Approved 8583	RAYOS Approved Use RAYOS is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation; for the treatment of certain endocrine conditions; for palliation of certain neoplastic conditions Launch Date 2012
Allergic conjunctivitis 101 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Acne rosacea 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Superficial punctate keratitis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Herpes zoster keratitis 44 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Iritis 43 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdf	Primary	Approved 8583	OMNIPRED Approved Use Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date 1973
Anaphylaxis 47 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Curative	Approved 8583	Prednisolut Approved Use Prednisolut is indicated in shock and emergency medicine: Shock due to a severe allergic reaction (anaphylactic shock), after previous treatment with epinephrine, progressive forms of allergic reactions in insect bites and snake bites
Brain edema 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Brain swelling (brain edema), triggered by brain tumor, neurosurgery, brain abscess, bacterial meningitis (meningitis).
Acute asthma attack 22 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Pulmonary edema 25 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown.
Rheumatoid arthritis 320 Sources: https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pil	Primary	Approved 8583	Prednisolut Approved Use Prednisolut is indicated for treatment of severe / life-threatening situations in the following rheumatic diseases: rheumatoid arthritis and still syndrome, felty syndrome, polymyalgia rheumatica, systemic juvenile idiopathic arthritis (eg breast disease, seropositive polyarthritis), collagenoses, vasculitides, rheumatic fever.

C_max

Value	Dose	Analyte	Population
0.054 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
33.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
41.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
43.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15.4 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
420.91 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
14.43 ng/mL DRUG LABEL https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/672212_2456402C1044_3_03#page=4	40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE blood	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
86 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
36 μg/dL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.484 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
298 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/12616672/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
358 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
387 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
97 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2408.1 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.025 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0173 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.085 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.0601 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8513854/	60 mg single, enteral dose: 60 mg route of administration: Enteral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29329497/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.85 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17925494	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.6 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4 h OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
30 min OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/343018_2456405D1027_2_016_1F.pdf#page=31	20 mg single, intramuscular dose: 20 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
25 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE HEMISUCCINATE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	1200 mg single, intravenous dose: 1200 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
50% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2199128		PREDNISONE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
20% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021959s004lbl.pdf	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
10% OTHER https://www.pdr.net/drug-summary/Omnipred-prednisolone-acetate-1102.1749#15		PREDNISOLONE plasma	Homo sapiens
23% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4084667/	75 mg single, intravenous dose: 75 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PREDNISOLONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183	Sources: https://doi.org/10.1016/B978-0-12-385157-4.00633-3 https://pubmed.ncbi.nlm.nih.gov/33663183
5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	Disc. AE: Vertigo, Abdominal pain upper... AEs leading to discontinuation/dose reduction: Vertigo (1%) Abdominal pain upper (1%) Gastroesophageal reflux disease (1%) Intestinal functional disorder (1%) Nausea (1%) Dizziness (1%) Aphasia (1%) Headache (1%) Renal pain (1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
1 % 4 times / day multiple, ophthalmic Recommended Dose: 1 %, 4 times / day Route: ophthalmic Route: multiple Dose: 1 %, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/	Sources: https://pubmed.ncbi.nlm.nih.gov/17762913/

AEs

AE	Significance	Dose	Population
Abdominal pain upper	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Aphasia	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Dizziness	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Gastroesophageal reflux disease	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Headache	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Intestinal functional disorder	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Nausea	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Renal pain	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf
Vertigo	1% Disc. AE	5 mg 1 times / day steady, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: steady Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202020Orig1s000MedR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	11-beta-HSD2 48 11-beta-HSD1 33 P-gp 2052	P-gp 301 BCRP 101 MRP1 74 MRP4 53 MRP5 45 ABCC12 43 MRP2 146 MRP3 83

Drug as perpetrator

Target	Modality	Activity
ABCC12 43	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
BCRP 985	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP1 232	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP3 326	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	no
MRP4 345	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP5 80	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
P-gp 1932	inducer 1966 Sources: https://www.sciencedirect.com/science/article/pii/S0143400412002895 Page: -	no
MRP2 625	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/15979871/ Page: -	yes

Drug as victim

Target	Modality	Activity
11-beta-HSD2 48	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	major
11-beta-HSD1 33	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	minor
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349812/ Page: -	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:8382	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8382
ChemicalBook	CB44844383	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB44844383
ChemicalBook	CB6716222	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6716222
eMolecules	29549912	https://www.emolecules.com/cgi-bin/more?vid=29549912
eMolecules	29703823	https://www.emolecules.com/cgi-bin/more?vid=29703823
eMolecules	31411020	https://www.emolecules.com/cgi-bin/more?vid=31411020
eMolecules	494851	https://www.emolecules.com/cgi-bin/more?vid=494851
MolPort	MolPort-001-740-041	https://www.molport.com/shop/molecule-link/MolPort-001-740-041
Selleck Chemicals	Prednisone	http://www.selleckchem.com/products/Prednisone.html
ZINC	ZINC000003875357	http://zinc15.docking.org/substances/ZINC000003875357
ChEBI	CHEBI:8378	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8378
ChemicalBook	CB4109000	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4109000
eMolecules	30512726	https://www.emolecules.com/cgi-bin/more?vid=30512726
eMolecules	31411129	https://www.emolecules.com/cgi-bin/more?vid=31411129
eMolecules	36644749	https://www.emolecules.com/cgi-bin/more?vid=36644749
eMolecules	511677	https://www.emolecules.com/cgi-bin/more?vid=511677
MolPort	MolPort-002-507-147	https://www.molport.com/shop/molecule-link/MolPort-002-507-147
Selleck Chemicals	Prednisolone(Hydroretrocortine)	http://www.selleckchem.com/products/Prednisolone(Hydroretrocortine).html
ZINC	ZINC000003833821	http://zinc15.docking.org/substances/ZINC000003833821

PubMed

Title	Date	PubMed
Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone.	1993	8513854
Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid.	1999 Jan	9923789
Leucocytoclastic vasculitis and indinavir.	2000 Nov	11069541
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.	2001	11223743
Bilateral empyema caused by adult-onset Still's disease.	2001	11223737
Choroidal granulomas in systemic sarcoidosis.	2001	11217928
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.	2001	11215697
Effect of dexmedetomidine on the release of [3H]-noradrenaline from rat kidney cortex slices: characterization of alpha2-adrenoceptor.	2001 Apr	11137626
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer.	2001 Feb	11223670
Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.	2001 Feb	11216711
Primary central nervous system lymphoma in childhood presenting as progressive panhypopituitarism.	2001 Feb	11216706
Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia.	2001 Feb	11216703
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.	2001 Feb	11211616
The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy.	2001 Feb	11207635
Mycophenolic acid plasma concentrations: influence of comedication.	2001 Feb	11206040
Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial.	2001 Feb	11205648
Recalcitrant allergic contact dermatitis from azathioprine tablets.	2001 Feb	11205401
Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.	2001 Feb	11182026
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].	2001 Feb	11181327
Idiopathic leukonychia totalis and partialis in a 12-year-old patient.	2001 Feb	11174421
Perinuclear antineutrophilic cytoplasmic antibody-positive cutaneous polyarteritis nodosa associated with minocycline therapy for acne vulgaris.	2001 Feb	11174376
Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years.	2001 Feb	11168956
Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis.	2001 Feb	11168951
Idiopathic IgA nephropathy with segmental necrotizing lesions of the capillary wall.	2001 Feb	11168950
Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.	2001 Feb	11168516
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.	2001 Feb 1	11157012
Sample size calculations for the two-sample problem using the multiplicative intensity model.	2001 Feb 28	11223901
Remission of precapillary pulmonary hypertension in systemic lupus erythematosus.	2001 Jan	11220068
Pyodera gangrenosum after aortic valve replacement.	2001 Jan	11216779
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.	2001 Jan	11212161
Gingival overgrowth as the initial paraneoplastic manifestation of Hodgkin's lymphoma in a child. A case report.	2001 Jan	11210066
Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome.	2001 Jan	11182286
Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease.	2001 Jan	11168510
A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.	2001 Jan	11168504
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.	2001 Jan	11168503
Multiple myeloma in elderly patients: presenting features and outcome.	2001 Jan	11168502
Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results.	2001 Jan	11166613
Immunosuppression as adjuvant therapy for biliary atresia.	2001 Jan	11150442
Biliary stricture secondary to donor B-cell lymphoma after orthotopic liver transplantation.	2001 Jan	11150426
Efficacy of parenteral methotrexate in refractory Crohn's disease.	2001 Jan	11136276
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.	2001 Jan 1	11149716
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	2001 Jan 1	11148572
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.	2001 Jan 15	11208830
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.	2001 Jan 16	11177311
Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection.	2001 Jan 27	11213064
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study.	2001 Jan 3	11136838
Autologous bone marrow transplantation for aggressive non-Hodgkin's lymphoma: lessons learned and challenges remaining.	2001 Jan 3	11136829
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.	2001 Mar 1	11222362
[Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablets in 2 to 12-years-old children].	2004 Sep	15351007
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis.	2008 Feb 1	17988236

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:30 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:30 GMT 2025`
Record UNII	D345THM53T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PREDNISOLONE METASULFOBENZOATE SODIUM

Preferred Name

English

PREDNISOLONE SODIUM METAZOATE

Official Name

English

PREDNISOLONE SODIUM METASULFOBENZOATE

Common Name

English

Prednisolone Metasulfobenzoate Sodium [WHO-DD]

Common Name

English

PREDNISOLONE, 21-M-SULFOBENZOATE SODIUM SALT

Common Name

English

PREDNISOLONE SODIUM 21-METASULPHOBENZOATE

Common Name

English

ATL-2502

Code

English

PREDNISOLONE SODIUM METASULPHOBENZOATE

Common Name

English

PREDNISOLONE SODIUM METAZOATE [USAN]

Common Name

English

PREDNISOLONE METASULFOBENZOATE SODIUM [MART.]

Common Name

English

PREDNISOLONE 21-M-SULFOBENZOATE SODIUM SALT

Common Name

English

SODIUM 3-(((11.BETA.,17-DIHYDROXY-3,20-DIOXOPREGNA-1,4-DIEN-21- YL)OXY)CARBONYL)BENZENESULPHONATE

Common Name

English

SODIUM 3-(((11.BETA.,17-DIHYDROXY-3,20-DIOXOPREGNA-1,4-DIEN-21- YL)OXY)CARBONYL)BENZENESULFONATE

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 11,17-DIHYDROXY-21-((3-SULFOBENZOYL)OXY)-, SODIUM SALT (1:1), (11.BETA.)-

Common Name

English

PREDNISOLONE 21-M-SULFOBENZOATE SODIUM SALT [MI]

Common Name

English

(11.BETA.)-11,17-DIHYDROXY-21-((3-SULFOBENZOYL)OXY)PREGNA-1,4-DIENE-3,20-DIONE MONOSODIUM SALT

Common Name

English

PREDENEMA

Brand Name

English

PREDNISOLONE SODIUM 21-M-SULFOBENZOATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C521